1. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Issue 10218 (11th January 2020) Authors: Mateos, Maria-Victoria; Cavo, Michele; Blade, Joan; Dimopoulos, Meletios A; Suzuki, Kenshi; Jakubowiak, Andrzej; Knop, Stefan; Doyen, Chantal; Lucio, Paulo; Nagy, Zsolt; Pour, Ludek; Cook, Mark; Grosicki, Sebastian; Crepaldi, Andre; Liberati, Anna Marina; Campbell, Philip; Shelekhova, Tatiana; Yo... Journal: Lancet Issue: Volume 395:Issue 10218(2019) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗